Trial Profile
Phase II Trial of Metronomic Eribulin (Halaven) In Pretreated Metastatic Breast Cancer (MBC)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Eribulin (Primary)
- Indications Advanced breast cancer; Male breast cancer
- Focus Therapeutic Use
- 01 Jul 2021 Results published in the Breast Cancer Research and Treatment
- 17 Oct 2019 Status changed from active, no longer recruiting to completed.
- 09 Nov 2018 Planned primary completion date changed from 1 Aug 2018 to 4 May 2019.